Healthcare shares were generally flat in pre-market trade
In healthcare stocks news, Regado BioSciences (
) has announced the Data Safety Monitoring Board has initiated an
unplanned review of data from the REGULATE-PCI trial, a Phase 3
The trial enrolled 13,200 patients with acute coronary syndromes
undergoing percutaneous coronary intervention. Patient enrollment
has been paused until the DSMB has completed its analysis and
communicated its recommendations, anticipated within the next eight
Shares of RGDO are down in early
with a 52-week range of $4.27 - $14.10.
And, PTC Therapeutics, Inc. (
) initiated a global confirmatory Phase 3 clinical trial of
Translarna, an investigational new drug, in patients with nonsense
mutation cystic fibrosis.
Nonsense mutations within cystic fibrosis are categorized as
Class I mutations, a severe form of CF that results in little or no
production of the CFTR protein.
Finally, Tekmira Pharmaceuticals (TKMR, TKM.TO) said it has been
advised by the U.S. FDA that the TKM-Ebola Phase I healthy
volunteer clinical study has been placed on clinical hold.
The dual-listed biopharmaceutical company said the study has
been put on hold, pending additional data related to the mechanism
of cytokine release, observed at higher doses, to ensure the safety
of healthy volunteer subjects.